Menke A, Heitplatz B, Van Marck V, Pavenstadt H, Jehn U
Case Rep Nephrol Dial. 2024; 14(1):20-29.
PMID: 38370571
PMC: 10871737.
DOI: 10.1159/000536448.
Lomuscio M, Abate C, Alberga D, Laghezza A, Corriero N, Colabufo N
Mol Pharm. 2023; 21(2):864-872.
PMID: 38134445
PMC: 10853961.
DOI: 10.1021/acs.molpharmaceut.3c00964.
Chu C, Hwang J
Expert Opin Drug Saf. 2020; 20(3):349-362.
PMID: 33306921
PMC: 10591488.
DOI: 10.1080/14740338.2021.1859476.
Abdelhameed A, Attwa M, Kadi A
Molecules. 2020; 25(21).
PMID: 33126762
PMC: 7663698.
DOI: 10.3390/molecules25215004.
Nasri H, Joukar S, Kheradmand H, Poursalehi H, Dabiri S
Med Princ Pract. 2015; 25(2):150-4.
PMID: 26544718
PMC: 5588350.
DOI: 10.1159/000442202.
Glucosylceramide and lysophosphatidylcholines as potential blood biomarkers for drug-induced hepatic phospholipidosis.
Saito K, Maekawa K, Ishikawa M, Senoo Y, Urata M, Murayama M
Toxicol Sci. 2014; 141(2):377-86.
PMID: 24980264
PMC: 4271040.
DOI: 10.1093/toxsci/kfu132.
Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B Inhibitor.
Chang J, Ciaccio P, Schroeder P, Wright L, Westwood R, Berg A
J Toxicol Pathol. 2014; 27(1):31-42.
PMID: 24791065
PMC: 4000071.
DOI: 10.1293/tox.2013-0033.
Identification of drugs inducing phospholipidosis by novel in vitro data.
Muehlbacher M, Tripal P, Roas F, Kornhuber J
ChemMedChem. 2012; 7(11):1925-34.
PMID: 22945602
PMC: 3533795.
DOI: 10.1002/cmdc.201200306.
Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction.
Funk R, Krise J
Mol Pharm. 2012; 9(5):1384-95.
PMID: 22449202
PMC: 3348458.
DOI: 10.1021/mp200641e.
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
Ahn J, Wee W, Lee J, Hyon J
Korean J Ophthalmol. 2011; 25(5):355-7.
PMID: 21976946
PMC: 3178773.
DOI: 10.3341/kjo.2011.25.5.355.
Mechanisms for Kir channel inhibition by quinacrine: acute pore block of Kir2.x channels and interference in PIP2 interaction with Kir2.x and Kir6.2 channels.
Lopez-Izquierdo A, Arechiga-Figueroa I, Moreno-Galindo E, Ponce-Balbuena D, Rodriguez-Martinez M, Ferrer-Villada T
Pflugers Arch. 2011; 462(4):505-17.
PMID: 21779761
DOI: 10.1007/s00424-011-0995-5.
Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.
Waldhauser K, BRECHT K, Hebeisen S, Ha H, Konrad D, Bur D
Br J Pharmacol. 2008; 155(4):585-95.
PMID: 18604229
PMC: 2579668.
DOI: 10.1038/bjp.2008.287.
The anomalous pharmacokinetics of amiodarone explained by nonexponential tissue trapping.
Weiss M
J Pharmacokinet Biopharm. 2000; 27(4):383-96.
PMID: 10826129
DOI: 10.1023/a:1020965005254.
Regulation of cardiolipin biosynthesis in the heart.
Hatch G
Mol Cell Biochem. 1996; 159(2):139-48.
PMID: 8858564
DOI: 10.1007/BF00420916.
Lipidosis of the dorsal root ganglia in rats treated with an almitrine metabolite.
Yamanaka Y, Sakamoto E, Sakuma Y, Uno H, Koyama T, Izawa Y
Arch Toxicol. 1995; 69(6):391-6.
PMID: 7495377
DOI: 10.1007/s002040050189.
Experimental lipidosis of the inner ear.
BICHLER E, SPOENDLIN H
Arch Otorhinolaryngol. 1980; 229(3-4):201-7.
PMID: 7469944
DOI: 10.1007/BF02565523.
Tamoxifen retinopathy.
McKeown C, Swartz M, Blom J, Maggiano J
Br J Ophthalmol. 1981; 65(3):177-9.
PMID: 7225310
PMC: 1039458.
DOI: 10.1136/bjo.65.3.177.
Adrenocortical function of rats under prolonged administration of lipidosis-inducing drugs.
Duncker G, Hartmann F, Mohr K
Naunyn Schmiedebergs Arch Pharmacol. 1982; 321(4):341-6.
PMID: 7167207
DOI: 10.1007/BF00498524.
Effects of chloroquine and Nifedipine on the phospholipid content and enzyme activity in the subcellular fraction of ischemic rat liver.
Kayawake S, NARBAITZ R, Kako K
Basic Res Cardiol. 1982; 77(2):140-57.
PMID: 7092773
DOI: 10.1007/BF01908168.
Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity.
Hostetler K, Hall L
Proc Natl Acad Sci U S A. 1982; 79(5):1663-7.
PMID: 6951205
PMC: 346036.
DOI: 10.1073/pnas.79.5.1663.
